AVAILABLE MEDICINE FOR Isavuconazole
There are no products to list.
Introduction to Isavuconazole
Trientine Hydrochloride is a chelating agent used primarily in the treatment of Wilson's disease, a genetic disorder that leads to excessive copper accumulation in the body. By binding to copper in the bloodstream, Trientine facilitates its excretion through urine, helping to reduce copper levels and prevent the associated toxic effects on the liver and brain.
How it works
The mechanism of action involves the formation of a stable complex with copper ions, promoting their elimination from the body. This property is particularly beneficial in patients who cannot tolerate traditional therapies such as penicillamine, another chelating agent. Trientine provides an alternative option for managing Wilson's disease effectively.
Side effects of Trientine
Trientine is usually administered orally, and while it is generally well-tolerated, potential side effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Rare but serious side effects can include proteinuria and liver toxicity, necessitating regular monitoring of renal and liver function during treatment.
The FDA approved Trientine Hydrochloride in 1985, recognizing its critical role in managing Wilson's disease, particularly in patients who experience adverse effects with other treatments. Healthcare providers need to assess individual patient responses to therapy and adjust treatment plans accordingly.
With its proven efficacy and safety profile, Trientine Hydrochloride remains a key component in the therapeutic arsenal for Wilson's disease, helping patients manage their condition and prevent long-term complications associated with copper accumulation.
